ducovest

FTXH:NSD-First Trust Nasdaq Pharmaceuticals ETF (USD)

EQUITY | Health | NASDAQ Global Market

Last Closing

USD 27.2351

Change

0.00 (0.00)%

Market Cap

USD 1.90M

Volume

1.31K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of the Nasdaq US Smart Pharmaceuticals Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in common stocks that comprise the index. The index is designed to select pharmaceuticals stocks from the base index based on a ranking methodology of three price factors which aims to select companies that exhibit: strong growth through high average 3-, 6-, 9- and 12-month price return; value; and low expected volatility based on historical stock price fluctuation. It is non-diversified.

Company Website : www.ftportfolios.com

Currency: USD

Country : USA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-28 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
IBB iShares Biotechnology ETF

N/A

 USD 6.53B
PPH VanEck Pharmaceutical ETF

N/A

 USD 0.60B
BBH VanEck Biotech ETF

N/A

 USD 0.40B
PSCH Invesco S&P SmallCap Health Ca..

N/A

 USD 0.18B
PTH Invesco DWA Healthcare Momentu..

N/A

 USD 0.12B
GNOM Global X Genomics & Biotechnol..

N/A

 USD 0.07B
CNCR Loncar Cancer Immunotherapy ET..

N/A

 USD 0.01B

ETFs Containing FTXH

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.33% 63% D 54% F
Dividend Return 1.19% 83% B 22% F
Total Return 3.52% 63% D 51% F
Trailing 12 Months  
Capital Gain 2.33% 63% D 54% F
Dividend Return 1.19% 83% B 22% F
Total Return 3.52% 63% D 51% F
Trailing 5 Years  
Capital Gain 16.71% 75% C 62% D
Dividend Return 6.54% 71% C- 20% F
Total Return 23.25% 75% C 59% D-
Average Annual (5 Year Horizon)  
Capital Gain 4.89% 88% B+ 53% F
Dividend Return 6.06% 88% B+ 51% F
Total Return 1.17% 75% C 32% F
Risk Return Profile  
Volatility (Standard Deviation) 8.34% 100% F 90% A-
Risk Adjusted Return 72.60% 88% B+ 88% B+
Market Capitalization 1.90M 25% F 16% F

Key Financial Ratios

  Ratio vs. Industry/Classification (Health) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 27.20 50% 45%
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.